Beating COVID-19: Insights and strategies for new vaccines and therapies
The outbreak of COVID-19, caused by the new virus SARS-CoV-2, has spread rapidly across the world. Since the first report from Wuhan, China on December 31, 2019, the total numbers of confirmed cases and COVID-19-related deaths worldwide have continued to escalate. Now declared a pandemic by the World Health Organization (“WHO”), COVID-19 has already overwhelmed healthcare systems in many countries and is expected to impose a major impact on the world economy.
Global vaccine trends: R&D and market insights driving new opportunities
Vaccines save millions of lives each year. By providing large-scale protection against serious diseases, vaccination programs proved to be one of the greatest public health achievements of the 20th century. Thanks to the advent of recombinant DNA technology and advanced multivalent vaccines, coupled with the ground-breaking innovation of cancer vaccines, the scope of vaccines continues to expand.
Gene and cell therapy: The R&D and market insights you need to get a competitive edge
Gene and cell therapies are now providing patients with treatments for many traditionally incurable diseases. These clinical successes are likely to be just the tip of the iceberg—the full promise of this field is yet to be realized. Pharmaceutical companies are therefore investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development.
Unlocking the full potential of therapeutic fusion proteins: R&D insights to help you get ahead
According to Yingzhu Li, Ph.D., Information Scientist and a contributing author on this blog post, organizations seeking innovative initiatives to accelerate the delivery of drugs to patients must stay abreast of the rapid developments in this area. CAS has collaborated with the National Science Library, Chinese Academy of Sciences (NSL) to produce a whitepaper on therapeutic proteins that's designed to give you the complete picture of the therapeutic fusion protein landscape and help you to identify the most promising opportunities. Here we've provided some key highlights from this useful resource, and how these insights could help your business gain the competitive advantage.
Realizing the potential of therapeutic antibodies: Insights into a changing landscape
With the rising potential for lucrative financial returns—the global market for therapeutic antibodies is expected to reach $115 billion in 2022—drug companies are investing heavily, which in turn is further fueling R&D developments in this area. For companies looking to expand their portfolios or jump into antibody therapeutics for the first time, the challenge is staying abreast of new developments. To help, CAS collaborated with the National Science Laboratory, Chinese Academy of Sciences (NSLC) to produce a whitepaper giving a detailed picture of the industry landscape, shedding light on emerging trends to identify potential commercial opportunities.